Baculovirus-mediated protein expression is one of the most popular vehicles for the overproduction of recombinant proteins, which are required for the structural and functional study of therapeutically relevant biomolecules. It has many advantages including high expression levels, posttranslational modification, and the capacity to simultaneously express multiple gene products. Typically, before any largescale expression work can commence, a myriad of optimization experiments are required to ensure the most appropriate expression conditions. As part of these studies, the titer of the recombinant viral stock is determined, thereby allowing the calculation of multiplicity of infections (MOIs) and ensuring cross-referencing and reproducibility in subsequent experiments. Baculovirus titer has traditionally been calculated using plaque assay (1), end point dilution (2), or immunoassay (3, 4) methodologies. In addition, several other strategies have been published, which include the determination of viral titer by real-time PCR (5) and a rapid antibody-based approach that allows viral titer determination in 10 h (6). All of these approaches have their own respective merits, however, they all share an overriding problem in that they take considerable periods of time to complete and/or can be difficult to interpret, giving rise to high variability between users. Therefore, despite the popularity of the baculovirus expression system in protein production laboratories worldwide, there is no fast, reliable, and inexpensive method of virus titer determination. We have therefore developed an automated method for the determination of baculovirus titer that uses green fluorescent protein (GFP)-linked coexpression plasmids similar to those recently described (7) and the Agilent 2100 Bioanalyzer (Agilent Technologies UK Ltd., Stockport, UK) to generate quick, highly reproducible viral titer estimates.
An XhoI-KpnI flanking GFP fragment was generated by standard PCR and subcloned into the p10 multiple cloning site (MCS) of pFastBac Dual™ (Invitrogen, La Jolla, CA, USA) to create a GFP coexpression plasmid compatible with the Bac-to-Bac ® Expression System (Invitrogen) (8, 9) . GFP pFastBac Dual was transposed into DH10Bac™ competent cells (both from Invitrogen), and recombinant bacmid was isolated following the manufacturer's instructions. Bacmid was then transfected into Sf21 cells, and high titer recombinant virus was produced. Viral titer was calculated using a standard viral plaque assay (1), the BacPAK™ immunoassay kit (BD Biosciences, San Jose, CA, USA) or the Agilent 2100 Bioanalyzer, following the manufacturer's instructions or as described in the figure legends.
In an initial experiment to ascertain whether recombinant baculovirus-expressing GFP could be detected using the Agilent 2100 Bioanalyzer, we infected a 50-mL culture of Sf21 cells with 1 mL of GFP virus. Following incubation for 48 h at 27°C, the cells were harvested, stained with the live cell dye carboxynaphthofluorescein diacetate (CBNF; Molecular Probes, Eugene, OR, USA), and analyzed using the Agilent 2100 Bioanalyzer. Figure 1 shows that 13.3% of live CBNF cells can be cross-gated with GFP fluorescence. Determining the number of CBNF-positive cells and the number of GFP-expressing cells also allows the calculation of the viral titer using the equation described by Berns and Giraud (10) . Viral titer (IU/ mL) can be calculated from the number of GFP-expressing cells divided by the volume of virus added, multiplied by the number of CBNF-labeled cells, and corrected for dilution.
The calculated value is 1.29 × 10 6 IU/mL and compares favorably with the viral titer calculated using the traditional plaque assay [4.1 × 10 6 plaque-forming units (pfu)/mL] or the BacPAK immunoassay (6.4 × 10 6 IU/ mL). It is noteworthy that since Sf21 cells are maintained in suspension culture throughout the course of the experiment (and are not immobilized as is the case in plaque and immunological methodologies), there is a chance that secondary infections may occur, thereby giving rise to overestimates of viral titers. However, based on the estimates given above, the method derived in this paper appears to provide a value that is actually slightly lower than the other approaches. This suggests that such concerns are not a major issue, although further study is required before a definitive conclusion can be drawn. In a separate experiment, we also tested the sensitivity of the method. Table 1 shows that after 48 h, the number of GFP-gated events in Sf21 cells infected with GFP-containing baculovirus drops from 86 (9.8% gated) to 4 (1.4% gated) when the virus added is diluted from 10 -1 through to 10 -3 . Conversely, Sf21 cells when infected with the GFP-minus baculovirus consistently show only 3-4 GFP-gated events (0.5%-1% gated). This small number of events presumably represents background fluorescence because no GFP is present in any of these samples. Taken together, this suggests that the GFP-containing virus is effectively removed from the cells by dilutions at 10 -3 and beyond. However, it must be stressed that for each recombinant virus studied, the point at which the virus is effectively neutralized by dilution will vary considerably. a viral titer of 10 8 /mL, the use of a 10 -1 dilution to calculate titer could cause significant secondary infections, giving rise to erroneous results. We therefore recommend that a serial dilution profile is performed on each viral stock to ascertain the most appropriate conditions for the calculation of viral titer when using this method. Finally, to ascertain the reproducibility of the assay and to identify any variability between cell fluorescence LabChips ® (Cell Fluorescence LabChip Kit; Agilent Technologies UK Ltd.), we infected four flasks with GFP and analyzed them on multiple chips. Figure 2 shows that for each flask infected with GFP-containing baculovirus, the number of total cell events, the number of live CBNF events, and the number of GFP-gated events calculated are in extremely close agreement. Similarly, this pattern is also observed between different chips, suggesting the high reproducibility of the system. In summary, we report the development of a fast and highly reproducible method of calculating the viral titer of a baculovirus stock using the Agilent 2100 Bioanalyzer and the Cell Fluorescence LabChip Kit in concert with GFP baculovirus coexpression plasmids. The method here offers several advantages over alternative approaches for viral titer calculation. First, because data collection is automated by the Agilent 2100 Bioanalyzer, it does not rely on the operator to differentiate between infected and noninfected cells. Sf21 cells (6 × 50 mL volumes; 0.5 × 10 6 cells/mL) were infected with a 1-mL volume of viral stock (GFPexpressing and non-GFP-expressing) diluted to 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , and 10 -6 and incubated for 48 h at 27°C. The cells were then harvested, and samples were prepared for analysis as described in the Figure 1 legend. Prior to dilution, the titers of both GFP-minus and GFP-containing baculovirus stocks were determined by plaque assay and normalized to 0.64 × 10 7 plaque-forming units (pfu)/mL by dilution. GFP, green fluorescent protein; CBNF, carboxynaphthofluorescein diacetate. To further facilitate baculovirusmediated expression using this system, we have adapted the GFP coexpression plasmid described above to make use of GATEWAY™ technology (Invitrogen). Thus, the use of the GATEWAY rapid cloning, in conjunction with the enhanced speed and reproducibility of the Agilent viral titer method described here, has enabled us to make significant savings in time and effort in our protein optimization studies. 
